Anavex Life Sciences Corp (AVXL)

[sokol]

I imagine everyone has seen this final program schedule/agenda for CTAD 2020 that is available and may be downloaded from the site provided below. Anavex’s presentation on November 6 at 11:00 EST will be an analysis of “Cognitive Outcome Measures Relevant in AD” of the PDD phase 2 clinical trial. So, this will be about cognitive measures from the PDD trial and how those measures apply to Alzheimer’s Disease.

“LB25 - ANAVEX®2-73 (blarcamesine) Currently in Phase 2b/3 Early Alzheimer’s Disease (AD): Analysis of Cognitive Outcome Measures Relevant in AD of Double-blind, Multicenter, Placebo-controlled Phase 2 Clinical Trial in 132 Patients with Parkinson’s Disease Dementia Dag Aarsland (1), Jaime Kulisevsky Bojarski (2), Mohammad Afshar (3), Coralie Williams (3), Frederic Parmentier (3), Martin Kindermans (3), Tayo Fadiran (4), Andy Mattai (4), Christopher U Missling (4), Walter E Kaufmann (4) (1)King’s College - London (United Kingdom); (2)University of Barcelona - Barcelona (Spain); (3)Ariana Pharma - Paris (France); (4)Anavex Life Sciences - New York, NY (United States)”


https://www.ctad-alzheimer.com/files/files/DIGITALprogram_CTAD2020_23oct.pdf